Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Miransertib × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Proteus Syndrome 1

Interventions

Specimen Handling 156 Magnetic Resonance Spectroscopy 128 Biopsy 99 pembrolizumab 86 Carboplatin 71 Cyclophosphamide 69 Paclitaxel 61 Cisplatin 59 Nivolumab 50 venetoclax 44 Radiotherapy 39 Gemcitabine 38 durvalumab 35 fludarabine 34 Rituximab 34 Bevacizumab 34 Dexamethasone 33 olaparib 32 atezolizumab 30 Prednisone 30 Oxaliplatin 29 X-Rays 28 Radiation 28 Ipilimumab 28 Cytarabine 27 Fluorouracil 26 Doxorubicin 26 Etoposide 25 Docetaxel 25 Lenalidomide 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04316546 2026-03-11

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting

Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡